DOCSLIB.ORG

Global Funding for Local Health Issues Jeremy Farrar Tells Fiona Fleck Why Global Health Research Must Go Local to Respond to Social Needs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Funding for Local Health Issues Jeremy Farrar Tells Fiona Fleck Why Global Health Research Must Go Local to Respond to Social Needs News Global funding for local health issues Jeremy Farrar tells Fiona Fleck why global health research must go local to respond to social needs. Q: The Wellcome Trust was set up in 1936 and has been a major player in many Jeremy Farrar is one of the world’s leading scientists in scientific advances, including sequenc- the field of infectious tropical diseases and since 2013 ing the human genome. It’s the world’s has been funding research globally as director of the second largest health research funder Wellcome Trust. From 1996 to 2013 he was the director after the Bill & Melinda Gates Founda- of the Oxford University research unit at the Hospital tion with an endowment of £19 billion for Tropical Diseases in Ho Chi Minh City, Viet Nam (US$ 29.5 billion). How did it feel to take that focuses on a wide range of infectious diseases over the reins as director of the Wellcome and became a leading centre for clinical research Trust in October 2013? Trust Wellcome Courtesy of the on emerging infections. He became a professor of A: Tremendous excitement but of Jeremy Farrar course also daunted by the responsibil- medicine at Oxford University in 2000. He is a member ity. The first outweighs the second, and of several World Health Organization (WHO) expert panels, including the you grasp the amazing opportunity and scientific and technical advisory committee on Ebola experimental interventions seek to contribute what you can. It is an and the emerging viral threats disease reference group. He is chairman of the enormous privilege and honour to be the WHO technical advisory group on dengue vaccines. Farrar trained in neurology director of such an organization. Hav- and infectious diseases in London, Edinburgh, San Francisco, Melbourne and ing been funded by the Wellcome Trust Oxford and has a PhD in immunology from Oxford University. as a researcher for almost two decades, I knew it very well from the outside. I knew its approach to research, its history and ethos and its values and many of the encourage teams of researchers to work initial data and apply for larger funds to people working there. This was incred- together within or between disciplines. further develop their projects. ibly helpful when I took over as director. Q: What other new initiatives have you Q: The Trust has been criticized in the Q: To what extent are you funding brought in? past for a lack of transparency over the individual researchers as opposed to A: Major scientific breakthroughs reasons for specific grant awards. How collaborations? are often made by relatively young peo- are you making the decision-making A: Globally there has been a trend ple in their 20s or 30s. I felt we need to process more transparent? over the past 20 years – and this has back young people taking on what might A: It is fair to say that we have not al- been true of almost every major funder seem improbable ideas and encour- ways provided as detailed and construc- – to increasingly focus both on indi- age them. There has been a tendency, tive feedback as we might have done. We viduals and very large consortiums of and not just at the Wellcome Trust, to get a huge number of applications and researchers. There are stellar individual move away from funding young people we cannot fund everyone. We are aware researchers out there and I strongly and award very large grants to people of the importance of feedback and aim to believe in funding the best people, but with long established track records. make more effort to provide feedback to I also believe in funding the best people We should support well-established unsuccessful applicants on the reasons working in great teams in great environ- scientists, but we risk disenfranchising why their applications were not funded ments. I also believe in funding young young people. We need to support the and how applications can be improved. people. Writing a book is an individual development of the next generation of This feedback is particularly important pursuit and there are areas of science research leaders. for young researchers. where a brilliant individual working alone makes a breakthrough. But the Q: What research funding model would Q: How do you decide who to fund? world of research is increasingly about you like to see and what are you doing A: In the Wellcome Trust we stimu- people working in multidisciplinary to support this? late ideas, advise and encourage research teams that consider the social context A: We need a mixed model which grant applicants. But most of the deci- of their work and are not working in a supports individuals throughout their sions on which grants receive funding scientific vacuum. While I believe we careers, encourages people to take risks are made by the committees of external must continue to support individual re- and, when driven by the research, allows experts that peer-review applications searchers to explore their dreams, there people to work in teams which take a and interview candidates. We are pres- is also a need to put back into the heart broad view of the question, including the ent at the committee meetings to ensure of research funding the opportunity for social context of the issues. Recently we that the process is fair and that the com- groups of researchers to work together took steps to increase the opportunities mittees’ work is aligned with the Trust’s and integrate the broader social conse- for early and mid-career researchers. strategic areas. The Trust decides the quences of their work. That is why we re- We also introduced seed grants to allow level of funding for each of our five stra- cently introduced collaborative grants to people who take on risky projects to gain tegic directions and each grant’s funding Bull World Health Organ 2015;93:367–368 | doi: http://dx.doi.org/10.2471/BLT.15.030615 367 News comes out of the funds that are flexibly will be led by the African Academy of severe acute respiratory syndrome allocated for the relevant strategic areas. Sciences. These two major initiatives (SARS) and H5N1 [avian influenza] support the development of the next outbreaks as well as from the develop- Q: How flexible is the Trust’s funding if the generation of research leaders based in ment of artemisinin-resistant malaria, committees make the decisions? Africa and India. I hope to work towards the current epidemic of MERS-CoV A: We are not fixed in our allocation further initiatives in the future in eastern [Middle East respiratory syndrome of funding and are able to move fund- Asia and other parts of the world. coronavirus] and many other national ing between our strategic directions to and regional epidemics over the last support the most promising research Q: One of the issues you have taken up is decade. We need to be much better pre- – research that we hope will have the antimicrobial resistance, why? pared to identify and report such infec- greatest impact. A: Antimicrobial resistance is the tions when they emerge as well as other most important emerging infectious potential public health threats. We also Q: Is there a shift away from awarding disease problem of our time. Currently need to be able to respond to these grants to recipients from the United King- we are all working in siloes. We need to threats in a much more decisive and dom and Commonwealth countries? bring together people working in differ- coordinated manner. Such a response A: The Commonwealth doesn’t ent disciplines: the human and animal requires much stronger public health come into it, we are a global organiza- health sector, people working in eco- and clinical systems in all countries but tion. We fund research in some Com- nomics, social sciences, anthropology, in particular low- and middle-income monwealth countries, but also in many law and policy to respond to this mas- countries. It also requires honest, others, such as China, Indonesia, Lao sive and growing problem. The whole transparent and accountable reporting People’s Democratic Republic, Nepal, of modern medicine relies on having and sharing of data, equitable sharing Viet Nam and others. Under my pre- effective antibiotics to prevent and treat of the benefits of that data (including decessor Mark Walport, the Trust’s infections. Without antibiotics basic sur- affordable and real-time access for spending on grants outside the United gery, chemotherapy for cancer and care diagnostics, drugs, vaccines or social Kingdom increased from approximately of patients with diabetes, for example, interventions) and much greater incen- 11–12% to 23–25% and I hope we can become very difficult if not impossible. tives for countries to work together and increase this even further. This is im- Addressing antimicrobial resistance is a share information. portant to the Trust’s history and goes major priority for the Wellcome Trust. back to our founder, Henry Wellcome, Q: How? who was an internationalist. We are a Q: What is the Trust doing to address A: I hope that all of us – commu- global funder of research with a focus the problem? nities, funders, public health, clinical, on support for research that can make A: We are working closely with governments, global organizations – can a difference to people’s lives. The United WHO, governments and philanthropic work together to really learn the tough Kingdom has a very strong basic science, organizations around the world to make lessons of the Ebola epidemic and put clinical and humanities research base, sure the issue of antimicrobial resistance in place the systems and approaches but the Trust is committed to global is a priority so that collectively we act to that we increasingly need so that we can health and is a global organization.
Load more

Recommended publications
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • Jeremy Farrar
    FEATURE The BMJ THE BMJ INTERVIEW BMJ: first published as 10.1136/bmj.n459 on 19 February 2021. Downloaded from [email protected] Cite this as: BMJ 2021;372:n459 http://dx.doi.org/10.1136/bmj.n459 Jeremy Farrar: Make vaccine available to other countries as soon as Published: 19 February 2021 our most vulnerable people have received it The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about controlling covid variants Mun-Keat Looi international features editor “Once the UK has vaccinated our most vulnerable among healthcare workers. We had no human communities and healthcare workers we should make immunity, no diagnostics, no treatment, and no vaccines available to other countries,” insists the vaccines. infectious disease expert Jeremy Farrar. This could Every country should have acted then. Singapore, avert further public health and economic disaster, China, and South Korea did. Yet most of Europe and he says, describing it as “enlightened self-interest, North America waited until the middle of March, and as well as the right ethical thing to do.” that defined the first wave. Countries including the In April 2020, soon after the first UK lockdown began, UK were unwilling to act early, before they felt Farrar predicted that the UK would have one of the comfortable; were unwilling to go deeper than they worst covid-19 death rates in Europe. As a member thought they had to; and were unwilling to keep of the Scientific Advisory Group for Emergencies restrictions in place for as long as was needed.
    [Show full text]
  • 2019-2020 PO No
    HOLY CROSS COLLEGE (AUTONOMOUS) Affiliated to Bharathidasan University Nationally Accredited (3rd Cycle) with 'A' Grade by NAAC College with Potential for Excellence. Tiruchirappalli - 620002. PG DEPARTMENT OF BIOCHEMISTRY Programme: M.Sc. BIOCHEMISTRY 2019-2020 PO No. Programme Outcomes Upon completion of the B.Sc. Degree Programme, the graduate will be able to PO-1 To enable to get quality education in the areas of Biochemistry PO-2 Acquire practical skills to gather information, assess, create and execute new ideas to develop entrepreneurial skills. PO-3 Gain Proficiency in basic laboratory techniques and able to apply the scientific method on lab to land PO-4 Inculcate a domestic and international perspective and be competent enough in the area of life sciences. PO-5 Learn to recognize potential laboratory safety and conserve nature and the environment. PSO No. Programme Specific Outcomes Upon completion of these courses the student would PSO-1 Will use current biochemical and molecular techniques and carry out experiments PSO-2 Monitoring the changes in modern life styles leads to modern diseases PSO-3 Develop skills in cultivation of plants. PSO-4 Prepare them to do higher studies in other biological fields like Genetic, Entomology, Biological Oceanography etc PSO-5 Developed critical thinking skills/laboratory techniques to be capable of designing, carrying out ,interpreting scientific experiments 1 HOLY CROSS COLLEGE (AUTONOMOUS) PG DEPARTMENT OF BIOCHEMISTRY (Students admitted from the year 2018 onwards) M.Sc. Biochemistry-Course
    [Show full text]
  • Financing Vaccines for Global Health Security
    NBER WORKING PAPER SERIES FINANCING VACCINES FOR GLOBAL HEALTH SECURITY Jonathan T. Vu Benjamin K. Kaplan Shomesh Chaudhuri Monique K. Mansoura Andrew W. Lo Working Paper 27212 http://www.nber.org/papers/w27212 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 May 2020 We thank Ellen Carlin, Doug Criscitello, Margaret Crotty, Narges Dorratoltaj, Per Etholm, Jeremy Farrar, Nimah Farzan, Mark Feinberg, Jose-Maria Fernandez, John Grabenstein, Peter Hale, Richard Hatchett, Peter Hotez, Daniel Kaniewski, Adel Mahmoud, Mike Osterholm, May 2020 Farrar, Nimah Kevin Outterson, Chi Heem Wong, CEPI leadership, and two reviewers and the editor for helpful comments and discussion, and Jayna Cummings for editorial assistance. Research support from the MIT Laboratory for Financial Engineering and the Warren Alpert Medical School of Brown University is gratefully acknowledged. The views and opinions expressed in this article are those of the authors only, and do not necessarily represent the views and opinions of any institution or agency, any of their affiliates or employees, any of the individuals acknowledged above, or the National Bureau of Economic Research. Funding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged, but no direct funding was received for this study and no funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript). At least one co-author has disclosed a financial relationship of potential relevance for this research.
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2019 Is © the Wellcome Trust and Is Licensed Under Creative Commons Attribution 2.0 UK
    Annual Report and Financial Statements 2019 Table of contents Report from Chair 3 Report from Director 5 Trustee’s Report 7 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 21 Financial Review 31 Structure and Governance 36 Social Responsibility 40 Risk Management 42 Remuneration Report 44 Remuneration Committee Report 46 Nomination Committee Report 47 Investment Committee Report 48 Audit and Risk Committee Report 49 Independent Auditor’s Report 52 Financial Statements 61 Consolidated Statement of Financial Activities 62 Consolidated Balance Sheet 63 Statement of Financial Activities of the Trust 64 Balance Sheet of the Trust 65 Consolidated Cash Flow Statement 66 Notes to the Financial Statements 67 Alternative Performance Measures and Key Performance Indicators 114 Glossary of Terms 115 Reference and Administrative Details 116 Table of Contents Wellcome Trust Annual Report 2019 | 2 Report from Chair During my tenure at Wellcome, which ends in The macro environment is increasingly challenging, 2020, I count myself lucky to have had the which has created volatility in financial markets. opportunity to meet inspiring people from a rich Q4 2018 was a very difficult quarter, but the diversity of sectors, backgrounds, specialisms resumption of interest rate cuts by the US Federal and scientific fields. Reserve underpinned another year of gains for our portfolio. We recognise that the cycle is extended, Wellcome’s achievements belong to the people and that the portfolio is likely to face more who work here and to the people we fund – it is challenging times ahead. a partnership that continues to grow stronger, more influential and more ambitious, spurred by The team is working hard to ensure that our independence.
    [Show full text]
  • Oxford Medicine
    Oxford Medicine THE NEWSLETTER OF THE OXFORD MEDICAL ALUMNI OXFORD MEDICINE • DECEMBER 2019 Courtesy of Ludwig Cancer Research of Ludwig Cancer Courtesy The Regius Professor Sir Tingewick is Does reflects on Peter Ratcliffe 80! Developmental 45 years in FRS, Nobel Dyslexia Really medicine Laureate Exist? 2 / OXFORD MEDICINE DECEMBER 2019 President’s Piece Welcome to the December Sir William Osler’s Centenary commemorations will issue of Oxford Medicine, the continue throughout the year in Oxford and beyond. newsletter for Oxford Medical The Osler Club is the first of a number of thriving Alumni (OMA) who have postgraduate Oxford medical societies we plan to feature. trained, taught, or worked at Professor Terence Ryan summarises this year’s five Osler Oxford. Professor John Morris, Club seminars exploring the Oslerian theme ‘For Health OMA president for the past and Wellbeing, Science and Humanities are one’. six years, handed the baton Tingewick is 80 this year. In 2019, as in 1939, Tingewick to me in September. It is a Dr Lyn Williamson, is still the most inclusive Oxford clinical student society. OMA President daunting task to take over from This year, every first year clinical student took part - someone so beloved and so that is 165! The show was a triumph of teamwork and respected, who has taught anatomy to generations talent. The legacy of camaraderie will last a lifetime - as of Oxford students and postgraduates, and shaped witnessed by the 80th anniversary celebrations. Dr Derek the preclinical school for many years. With his Roskell, Senior Tingewick Member for 25 years adds his characteristic kindness and wisdom, he said: ‘You will be fine - and I will be there to advise you’.
    [Show full text]
  • OVER £140 Prime Minister, the Rt Hon David Came
    PRIME MINISTER QUARTERLY INFORMATION: 1 APRIL – 30 JUNE 2011 GIFTS (RECEIVED) OVER £140 Prime Minister, The Rt Hon David Cameron MP Date gift From Gift Value Outcome received April 2011 Prime Minister of Furniture Over Held by Department Pakistan limit April 2011 Prime Minister of Rug Over Held by BHC Pakistan limit Islamabad April 2011 Italian Aeronautica Leather jacket Over Held by Department Militare limit April 2011 Portmeirion Potteries China Over Held by Department Group limit May 2011 President Obama and Silver jewellery and Over Held by Department Mrs Obama First Edition Book limit May 2011 President of Russia Painting Over Held by Department limit May 2011 President of France Pen Set and Over Held by Department Glassware limit June 2011 Prime Minister of Picture Over Held by Department Malaysia limit GIFTS (GIVEN) OVER £140 Prime Minister, The Rt Hon David Cameron MP Date gift From Gift Value Outcome given Nil return HOSPITALITY1 Prime Minister, The Rt Hon David Cameron MP Date Name of Organisation Type of Hospitality Received NIL RETURN 1 Does not normally include attendance at functions hosted by HM Government; ‘diplomatic’ functions in the UK or abroad, hosted by overseas governments; minor refreshments at meetings, receptions, conferences, and seminars; and offers of hospitality which were declined. OVERSEAS TRAVEL Prime Minister Date(s) of trip Destination Purpose of ‘No 32 (The Number of Total cost trip Royal) officials including travel Squadron’ accompanying and or ‘other Minister, where accommodation of RAF’ or non-scheduled
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Understanding the an English Agribusiness Lobby Group
    Understanding the NFU an English Agribusiness Lobby Group Ethical Consumer Research Association December 2016 Understanding the NFU - an English Agribusiness Lobby-group ECRA December 2016 1 Contents 1. Introduction – The NFU an English Agribusiness Lobby group 3 2. Economic Lobbying – undermining the smaller farmer 2.1 NFU and farm subsidies – promoting agribusiness at the expense of smaller farmers 11 2.2 NFU and TTIP – favouring free trade at the expense of smaller farms 15 2.3 NFU and supermarkets – siding with retailers and opposing the GCA 17 2.4 NFU and foot and mouth disease – exports prioritised over smaller producers 20 3. Environmental Lobbying – unconcerned about sustainability 3.1 NFU, bees and neonicotinoids – risking it all for a few pence more per acre 24 3.2 NFU and soil erosion – opposing formal protection 28 3.3 NFU and air pollution – opposing EU regulation 31 3.4 NFU, biodiversity and meadows – keeping the regulations away 33 3.5 NFU and Europe – keeping sustainability out of the CAP 41 3/6 NFU and climate change – a mixed response 47 3.7 NFU and flooding – not listening to the experts? 51 4. Animal interventions – keeping protection to a minimum 4.1 Farm animal welfare – favouring the megafarm 53 4.2 NFU, badgers and bovine TB – driving a cull in the face of scientific evidence 60 4.3 The Red Tractor label – keeping standards low 74 5. Social Lobbying – passing costs on to the rest of us 5.1 NFU and Organophosphates in sheep dip – failing to protect farmers’ health 78 5.2 NFU and road safety – opposing regulations 82 5.3 NFU and workers’ rights – opposing the Agricultural Wages Board 86 5.4 NFU and Biotechnology – Supporting GM crops 89 6.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]
  • Meeting Schedule/Structure
    Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ Tuesday 6th - Thursday 8th October 2020 (12.00-16.00 GMT daily) Programme Tuesday 6 October 12:00-12:15 Welcome Alan Hay, Francis Crick Institute, London, UK & Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA Introduction Jeremy Farrar, Wellcome Trust, London, UK Chairs TBC 12:15-12:40 COVID-19 Clinical Spectrum, Complications, and Coinfections Bin Cao, China-Japan Friendship Hospital, Beijing, China 12:40-13:00 COVID-19 Viral Replication Kinetics Malik Peiris, University of Hong Kong, HK SAR, China 13:00-13:20 COVID-19 Autopsy Findings Xiuwu Bian, China (TBC) 13:20-13:40 Immunopathogenesis of COVID-19 Peter Openshaw, Imperial College London, UK 13:40-14:00 Pathogenesis and Management of ARDS – Richard Wunderink, Northwestern University, Evanston, IL, USA 14:00-14:10 Comfort Break 14:10-15:10 Chairs TBC Oral Abstract Session 1 4 x 15 minute presentations (including Q&A) 15:10-15:20 Close of Day 1 Poster Viewing Page 1 of 3 Wednesday 7 October Chairs TBC 12:00-12:20 SARS-CoV-2 Antiviral Targets Mark Denison (accepted in principle) 12:20-12:40 Pre-clinical Models for Downselecting Candidates Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France 12:40-13:10 RECOVERY Trial and Strategies for Rapid Clinical Testing Peter Horby, Oxford, UK 13:10-13:30 Convalescent Plasma and Polyclonal Antibodies - Michael Joyner, Mayo Clinic, MN, USA 13:30-13:50 Monoclonal Antibodies Erica Saphire, La Jolla Institute for
    [Show full text]
  • Alagappa University M. Sc. Biotechnology
    ANNEXURE I M. Sc., Biotechnology (Specialization: Marine Biotechnology) CBCS Course Structure & Syllabus (For those who joined in July 2011 or after) Department of Biotechnology (UGC-SAP and DST-FIST & PURSE Sponsored Department) Alagappa University (A State University Accredited with “A” Grade by NAAC) Karaikudi 630 003 1 DEPARTMENT OF BIOTECHNOLOGY (UGC-SAP and DST-FIST & PURSE Sponsored Department) ALAGAPPA UNIVERSITY (A State University Accredited with “A” Grade by NAAC) M. Sc., Biotechnology Programme Choice Based Credit System (CBCS) For those who joined in July 2011 or after Course Structure S. Code Name of the Course Credits Marks No SEMESTER – I Int. Ext. Total 1. 501101 Core 1: Biochemistry 4 25 75 100 2. 501102 Core 2: Microbiology 4 25 75 100 3. 501103 Core 3: Molecular Biology and Genetics 4 25 75 100 4. 501104 Core 4: Cell Biology 4 25 75 100 5. 501105 Core 5: Lab I: Analytical Biochemistry 4 25 75 100 6. 501106 Core 6: Lab II: Microbiology 4 25 75 100 7. Elective 1 5 25 75 100 29 175 525 700 SEMESTER – II Int. Ext. Total 8. 501201 Core 7: Immunobiology 4 25 75 100 9. 501202 Core 8: Recombinant DNA Technology 4 25 75 100 10. 501203 Core 9: Plant Molecular Biology 4 25 75 100 11. 501204 Core 10: Lab III: Molecular Genetics 4 25 75 100 12. 501205 Core 11:Lab IV: Immunotechnology 4 25 75 100 13. Elective 2 5 25 75 100 25 150 450 600 SEMESTER – III Int. Ext. Total 14. 501301 Core 12: Bioinformatics 4 25 75 100 15.
    [Show full text]